Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 8 Hillside Ave Ste 207 MONTCLAIR NJ 07042-2129 |
Tel: | 1-212-5545466 |
Website: | www.fluoropharma.com |
IR: | See website |
Key People | ||
Walter W. Witoshkin Independent interim chairman of the board | Ambrose O. Egbuonu President, Treasurer, Company Secretary | Thomas H. Tulip Chief Executive Officer, Director | Frank I. Igwealor Chief Financial Officer, Controller, Director |
Business Overview |
FluoroPharma Medical, Inc. is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with initial applications in the area of cardiology. The Company is focused on the development of cardiovascular imaging agents that detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular imaging pharmaceutical product candidates: 18-F TPP (BFPET) and 18-F FCPHA (CardioPET). BFPET program employs a (18F)-labeled cationic lipophilic tetraphenylphosphonium ion as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD. It measures the extent and severity of cardiovascular disease through the detection of ischemic and infarcted myocardial tissue. CardioPET program employs Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD. |
Financial Overview |
For the fiscal year ended 31 December 2016, Fluoropharma Medical Inc revenues was not reported. Net loss applicable to common stockholders decreased 31% to $2.6M. Lower net loss reflects Gain on revaln of derivative warrant lia increase from $716K to $2.3M (income), General and administrative decrease of 31% to $1.7M (expense), Research and development decrease of 29% to $511K (expense). |